Change of Adviser

RNS Number : 7490Z
ReNeuron Group plc
31 May 2016
 

 

 

31 May 2016

AIM: RENE

 

ReNeuron Group plc

 

 

Change of Adviser

 

ReNeuron Group plc (the "Company") (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce the appointment of Stifel Nicolaus Europe Limited as Nominated Adviser and Broker to the Company with immediate effect. 

 

ENDS

ENQUIRIES:

 

 

ReNeuron

+44 (0)20 3819 8400

Olav Hellebø , Chief Executive Officer


Michael Hunt, Chief Financial Officer


Buchanan

+44 (0) 20 7466 5000

Mark Court, Sophie Cowles, Stephanie Watson




Stifel Nicolaus Europe Limited

+44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace (NOMAD and Broker)


 

 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

 

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.   

 

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPFFLFXQEFXBBE
UK 100

Latest directors dealings